respond

Zumo first to launch platform built to meet the tech requirements of the FCA’s new Financial Promotions Regime for Crypto Assets

Source Node:
Time Stamp: October 6, 2023 7:12 AM - Modified On: October 6, 2023 - Published By:
Source Cluster:
Republished By Plato

  The award-winning platform has set a new benchmark in consumer protection and regulatory alignment With some UK operators having to pause activity, Zumo’s financial promotions technical flow is now also available through its B2B API to support unregistered firms with remaining compliant after the 8 October deadline [London/Edinburgh - Friday 29 September 2023] Zumo, the UK-based digital-asset-as-a-service platform, has announced a significant industry milestone as it becomes the first digital asset platform to have integrated tech based requirements of the Financial Conduct Authority’s (FCA’s) new financial promotions regime for

The Collision of Titans: AI and Web3

Source Node:
Time Stamp: September 4, 2023 12:28 PM - Modified On: September 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Over the past decade, two titans have emerged from the tech realm, each promising to redefine the very fabric of our global infrastructure - Artificial Intelligence (AI) and Web3. But what happens when these two forces converge? Are we on the brink of a new digital renaissance or a potentially uncharted dystopia? Consider this: AI is, at its core, the embodiment of advanced logic and decision-making, a machine's ability to "think" and process information in ways eerily similar to humans. It's no longer just about algorithms; it's about creating synthetic

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating